Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICDs (implantable cardioverter defibrillators) look set to gain acceptance among physicians as the first-line treatment for heart patients

This article was originally published in Clinica

Executive Summary

The implantable cardioverter defibrillator (ICD) is already replacing drug therapy as the primary treatment for the prevention of potentially fatal ventricular arrhythmias. Neena Brizmohun reports from a conference where cardiologists examined the reasons behind the increase in ICD use.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT081457

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel